Pfizer could earn $15B-plus in COVID-19 vaccine sales: analyst

On the heels of Pfizer's $1.95 billion COVID-19 vaccine deal with the U.S. government, one analyst says the drugmaker could earn many more billions in revenue on its potential vaccine—if the program succeeds.